Core Insights - The company, Huaheng Biological, announced an investment of 320 million yuan to establish an "Artificial Intelligence Precision Fermentation and Protein Engineering Shared Demonstration Project" in Changfeng County, Hefei [1] - This investment aims to enhance production efficiency and product quality through advanced microbial fermentation technology and AI-driven process control [1] - The project is expected to take 36 months to complete and will be funded primarily through the company's own or self-raised funds [1] Investment Details - The total investment agreements signed by the company with the Changfeng (Shuangfeng) Economic Development Zone Management Committee in the past 12 months amount to 710 million yuan, including a previous agreement of 390 million yuan for a "AI-driven Biological Manufacturing R&D and Pilot Demonstration Base" [2] - The new project will be located at the intersection of Shuangfeng Road and Yingzhou Road in the Shuangfeng Economic Development Zone [1] Technological Advancements - The investment will leverage cutting-edge technologies in synthetic biology and metabolic engineering, transitioning biological manufacturing from traditional fermentation to precision and intelligence [1] - The company aims to establish an intelligent production system to meet market demands for high-quality, low-cost products, thereby enhancing its core competitiveness and maintaining its industry leadership [1]

Core Viewpoint - Company Huaheng Biological has announced a significant investment plan of 320 million yuan to establish an "AI Precision Fermentation and Protein Engineering Shared Demonstration Project" to maintain its industry leadership and meet market demands for high-quality, low-cost products [1] Group 1: Investment and Project Details - The investment will fund the construction of new production facilities, including workshops, finished goods warehouses, and office buildings, with a projected construction period of 36 months [1] - The funding will come from the company's own or self-raised funds, aimed at building an intelligent production system [1] Group 2: Financial Performance - In 2024, the company reported revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, but net profit fell by 57.80% to 190 million yuan [2] - The decline in net profit is primarily attributed to price pressures on valine products, which are at historical lows due to intensified market competition [2] - In Q1 2025, revenue grew by 37.20% to 687 million yuan, but net profit decreased by 40.98% to 51.1 million yuan [2] Group 3: Research and Development - The company has consistently increased its R&D expenditure from 30.12 million yuan in 2020 to 124 million yuan in 2024, totaling 395 million yuan over five years [3] - In 2024, the company achieved significant breakthroughs in major projects, advancing its product diversification strategy with key projects like bio-based succinic acid and 1,3-propanediol [3] - The company added 10 invention patents and 8 utility model patents in 2024, bringing the total to 78 invention patents and 77 utility model patents by the end of 2024 [3]

Core Viewpoint - The company, Huaheng Biotechnology, is investing 3.9 billion RMB to advance AI-driven biomanufacturing, establishing a research and pilot demonstration base for artificial intelligence in biomanufacturing [1][2]. Investment Purpose - The investment aims to transition biomanufacturing from traditional fermentation to precision and intelligence, ensuring the company maintains its industry leadership and meets market demands for high-quality, low-cost products [5]. - By integrating advanced microbial fermentation technology with AI, the company seeks to achieve real-time monitoring and optimization of production processes, enhancing both yield and quality [5]. - The investment will help establish an intelligent production system, improving the company's core competitiveness through precise control of fermentation parameters and the creation of a proprietary database for protein design [5]. Project Overview - Project Name: AI Precision Fermentation and Protein Engineering Shared Demonstration Project [9]. - Investment Amount: 3.2 billion RMB [9]. - Location: Changfeng County, Shuangfeng Economic Development Zone [9]. - Project Area: 64 acres [9]. - Expected Construction Period: 36 months [9]. - Construction will include new production workshops, finished goods warehouses, tank areas, office buildings, R&D buildings, and comprehensive buildings [9].

Core Viewpoint - Chinese enterprises are undergoing a critical transformation from a "manufacturing power" to an "innovation powerhouse" amid global supply chain restructuring and intensified technological competition [1] Group 1: Patent as a Strategic Armor - Chinese companies face dual pressures: the trend of "decentralization" in global supply chains and the shift from cost competition to value competition in the domestic market [2] - The "14th Five-Year Plan" emphasizes the need to build a strong intellectual property (IP) nation, highlighting the importance of IP protection for innovation-driven development [2] - According to the World Intellectual Property Organization (WIPO), China has maintained the highest number of invention patent applications globally for 12 consecutive years, but the number of patent infringement cases is also increasing [2] Group 2: Systemic Harm from Weak Patent Protection - Weak patent protection leads to systemic harm for enterprises and industries, resulting in market imitation that can significantly reduce sales and dampen R&D enthusiasm [3] - The phenomenon of "bad money driving out good" has previously caused several domestic sectors, such as solar energy and lithium batteries, to fall into "low-end involution" due to price wars stemming from inadequate patent protection [3] Group 3: The Case of Huaheng Biological - The ongoing patent infringement case involving Huaheng Biological and Huairui Biological is a significant example of IP protection in the biomanufacturing industry [4] - Huaheng Biological is the first global company to produce β-alanine using fermentation and enzyme engineering technology, with a core patent that enhances production efficiency and product competitiveness [4] - The patent in question is valid until 2037 and is crucial for the industry's innovation ecosystem; if infringement continues, it may lead to widespread imitation and damage the sector [5] Group 4: Strategic Upgrades in IP Protection - Huaheng Biological's proactive approach to IP protection includes independent R&D, patent portfolio development, and regular IP audits to identify infringement [6] - The transition from "passive defense" to "active shaping of the competitive environment" reflects a strategic upgrade in IP management [6] - In the era where "patents are king," the ability to build a "patent firewall" is essential for Chinese enterprises to navigate high-quality development and overcome bottlenecks in the global value chain [6]

Key Points - The article highlights various significant announcements from companies, including revenue growth, investment projects, and share buybacks [1][2] Company Announcements - Baili Electric's revenue from related businesses in 2024 will account for less than 1% of the company's total revenue [1] - Taihe Co., Ltd. plans to invest up to $150 million in a pesticide and functional chemicals project in Egypt [1] - Huakang Clean is expected to win a bid for the renovation of the second inpatient building at West China Hospital of Sichuan University [1] - YTO Express reported a revenue of 5.755 billion yuan from express products in April, a year-on-year increase of 16.32% [1] - Shentong Express reported a revenue of 4.118 billion yuan from express services in April, a year-on-year increase of 16.39% [1] - Kangping Technology plans to acquire 100% equity of Souluke Electronics for 198 million yuan [1] - Hexing Packaging intends to repurchase shares worth between 50 million to 100 million yuan [1] - Guangxi Media's controlling shareholder and its concerted parties plan to reduce their holdings by no more than 1% [1] - Huading Co., Ltd. plans to reduce its holdings by no more than 3% [1] - Jingu Co., Ltd. received a notification from a leading global new energy vehicle company [1] - Wanrun New Energy signed a business cooperation agreement with CATL, expecting a total supply volume of approximately 1.3231 million tons [1][2] Investment Projects - Huaheng Biological plans to invest 320 million yuan in an "AI Precision Fermentation and Protein Engineering Shared Demonstration Project" [1] Share Buybacks - Kesi Technology plans to repurchase shares worth between 30 million to 50 million yuan [1] - Zhaoxun Media intends to repurchase 1.66% to 3.33% of its shares [2]

Core Viewpoint - The company plans to invest 320 million yuan in an "AI-driven precision fermentation and protein engineering shared demonstration project" to maintain its industry leadership and meet market demand for high-quality, low-cost products [1][2]. Investment Details - The company signed an investment agreement worth 390 million yuan with the Anhui Changfeng (Shuangfeng) Economic Development Zone Management Committee for the construction of an AI-driven bio-manufacturing R&D and pilot demonstration base [1]. - The total investment agreements signed with the Anhui Changfeng (Shuangfeng) Economic Development Zone in the past 12 months amount to 710 million yuan, meeting the disclosure standards of the Sci-Tech Innovation Board [1]. Project Specifications - The project will include the construction of new production workshops, finished product warehouses, tank areas, office buildings, R&D buildings, and comprehensive buildings, with an estimated construction period of 36 months [2]. - Funding for the project will come from the company's own or self-raised funds [2]. Company Overview - The company focuses on synthetic biology technology and is engaged in the R&D, production, and sales of bio-based products, including amino acids, vitamins, and bio-based new material monomers [2]. - In 2024, the company achieved a revenue of 2.178 billion yuan, a year-on-year increase of 12.37%, and a net profit of 190 million yuan [2]. Technological Advancements - The company utilizes gene synthesis, gene editing, pathway assembly and optimization, and global cell optimization technologies to create new cell factories, accelerating the industrialization of scientific achievements [3]. - The development of AI technology is expected to enhance gene editing efficiency, metabolic pathway optimization, production process optimization, and protein design, further empowering breakthroughs in biosynthesis technology [3][4]. Production Innovation - The company aims to adopt advanced microbial fermentation technology combined with AI for precise control of the fermentation process, introducing automation equipment and control systems for real-time monitoring and optimization of production [4]. - The investment will help the company build an intelligent production system, enhancing its core competitiveness [4].

证券代码：688639 证券简称：华恒生物 公告编号：2025-024 http://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络互动 ??投资者可于 2025 年 05 月 20 日（星期二）至 05 月 26 日（星期一） 司邮箱 ahb@ehuaheng.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 安徽华恒生物科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 23 日发布公司 2024 年年度报告及 2025 年第一季度报告。为便于广大投资者更全面 深入地了解公司 2024 年度及 2025 年第一季度经营成果、财务状况，公司计划于 绩说明会，就投资者关心的问题进行交流。 安徽华恒生物科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ??会议召开时间：2025 年 05 月 27 日（星期二）14:00-15:00 ? 会议召开地点：上海证券交 ...

Core Viewpoint - Anhui Huaheng Biological Technology Co., Ltd. plans to invest RMB 320 million in the construction of an "Artificial Intelligence Precision Fermentation and Protein Engineering Shared Demonstration Project" to maintain its industry leadership and meet market demand for high-quality, low-cost products [1][2]. Investment Overview - The investment amount for the project is RMB 320 million, primarily funded by self-owned or self-raised funds, with a construction period of 36 months [1][2]. - The project is located in the northeast corner of the intersection of Shuangfeng Road and Yingzhou Road in the Shuangfeng Economic Development Zone, Changfeng County [1]. Decision and Approval Process - The investment decision was approved by the company's management and does not require board approval, as it falls within the management's authority [1][2]. - The company has signed a total of RMB 710 million in investment agreements with the Changfeng (Shuangfeng) Economic Development Zone Management Committee over the past 12 months [2]. Project Details - The project aims to utilize advanced microbial fermentation technology combined with artificial intelligence for precise control of the fermentation process, enhancing production efficiency and product quality [5]. - The project will establish a smart production system, improving the company's core competitiveness in the market [5]. Environmental and Safety Compliance - The company is required to adhere to national environmental protection standards and energy-saving regulations during the construction and operation of the project [4]. - The project must comply with safety management laws and regulations, ensuring proper handling of wastewater, waste gas, and solid waste [4].

重要内容提示： 会议召开时间：2025 年 05 月 27 日（星期二）14:00-15:00 证券代码：688639 证券简称：华恒生物 公告编号：2025-024 安徽华恒生物科技股份有限公司 关于召开2024 年度暨 2025年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 05 月 20 日（星期二）至 05 月 26 日（星期一） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公 司邮箱 ahb@ehuaheng.com 进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 安徽华恒生物科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 23 日发布公司 2024 年年度报告及 2025 年第一季度报告。为便于广大投资者更全面 深入 ...

公司于2024年5月25日与安徽长丰(双凤)经济开发区管理委员会签订了金额为 3.9亿元的投资协议，建设公司人工智能驱动生物制造研发及中试示范基地建设项目， 1 证券代码：688639 证券简称：华恒生物 公告编号：2025-023 安徽华恒生物科技股份有限公司 对外投资公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、投资情况概述 安徽华恒生物科技股份有限公司（以下简称"公司"）为保持公司行业领先地 位，实现公司的可持续发展，满足市场对高品质、低成本产品的需求，提高公司产 品的市场竞争力，拟投资人民币3.2亿元，建设"人工智能精准发酵及蛋白质工程共 享示范项目"（以下简称"项目"）。本次投资项目资金来源主要为自有或自筹资 金。预计建设期为36个月，项目建设地点位于长丰县双凤经济开发区双凤路与颍州 路交口东北角。 （一）对外投资的基本情况 （二）对外投资的决策和审批程序 投资标的名称：人工智能精准发酵及蛋白质工程共享示范项目 项目投资建设主体：安徽华恒生物科技股份有限公司 投资金额：人民币3.2亿元 ...